Aulinger BA,Bedorf A,Kutscherauer G,et al.Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes (T2D) utilizing DPP-4 inhibition and GLP-1-receptor blockade[J].Diabetes,2013,63(3):1079-1092.A
The dataset included initiations of various antidiabetic drugs, such as metformin (ATC code A10BA02), GLP-1 analogs (A10BJ), DPP-4 inhibitors (A10BH), SGLT2 inhibitors (A10BK), combinations of oral blood glucose-lowering drugs (A10BD), and insulin (A10A). Each drug purchase was assumed...
N. Using DPP-4 inhibitors to modulate beta cell function in type 1 diabetes and in the treatment of diabetic kidney disease. Expert. Opin. Investig. Drugs. 28(4), 377–388. https://doi.org/10.1080/13543 784.2019.1592156 (2019). 76. Elbarbary, N....
DPP-4 Inhibitors: Dipep- tidyl peptidase-4 inhibitors; EDN-1: Endothelin 1; eGFR: Estimated glomerular filtration rate; ELISA: Enzyme-linked immunosorbent assay; eNOS: Nitric oxide synthase 3 (endothelial cell); EPCs: Endothelial progenitor cells; FFM: Fat-free mass; GAPDH: Glyceraldehyde-3-pho...
Precision medicine in type 2 diabetes: clinical markers of insulin resistance are associated with altered short- and long-term glycemic response to DPP-4 inhibitor therapy Diabetes Care, 41 (2018), pp. 705-712 CrossrefView in ScopusGoogle Scholar 31 BL Strom, ME Buyse, J Hughes, BM Knoppers...
We use to think that the block size was decided by the encoder but after placing a 22-PvtPpr Newschain (with full hashlinks) together with an end result of a multi-million length top hashlink, we realized that the users device encoding the PvtPpr actually determines the size of a block...
Their chemical compositions were determined, and antioxidant activities were investigated on the basis of superoxide radical, hydroxyl radical, reducing power, DPP 正在翻译,请等待... [translate] a欢迎发表观点或输入您需要翻译的文本!Hot Stone Therapy Welcome text which expresses the viewpoint or inputs...
(weight loss) lactic acidosis, B12 deficiency Low-none Meglitinides Repaglinide Thiazolidinediones Pioglitazone -glucosidase Inhibitors GLP-1 agonists Miglitol Exenatide DPP-4 Inhibitors Sitagliptin SGL-2 Inhibitors Empagliflozin Amylin peptide analogs Pramlintide LDL: TG: HDL: LDL: TG: HDL: LDL: TG: ...
The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.
From a library of 4828 compounds, three inhibitors (K784-2660, 6484-0066, and E699-0153) were identified for their strong inhibitory effects on DPPIV. These inhibitors not only suppressed DPPIV activity in the ileum of mice, thereby reducing GLP-1 degradation, but also effectively inhibited ...